File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant

TitleHybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant
Authors
KeywordsAntigen expression
Core/shell nanoparticles
Delivery systems
Hybrid nanoparticle
Intravenous administration
Issue Date2019
PublisherRSC Publications. The Journal's web site is located at http://pubs.rsc.org/en/journals/journalissues/nr#!recentarticles&all
Citation
Nanoscale, 2019, v. 11 n. 45, p. 21782-21789 How to Cite?
AbstractFor efficient cancer vaccines, the antitumor function largely relies on cytotoxic T cells, whose activation can be effectively induced via antigen-encoding mRNA, making mRNA-based cancer vaccines an attractive approach for personalized cancer therapy. While the liposome-based delivery system enables the systemic delivery and transfection of mRNA, incorporating an adjuvant that is non-lipid like remains challenging, although the co-delivery of mRNA (antigen) and effective adjuvant is key to the activation of the cytotoxic T cells. This is because the presence of an adjuvant is important for dendritic cell maturation—another necessity for cytotoxic T cell activation. In the present work, we designed a poly (lactic-co-glycolic acid) (PLGA)-core/lipid-shell hybrid nanoparticle carrier for the co-delivery of mRNA and gardiquimod (adjuvant that cannot be incorporated into the lipid shell). We demonstrated in the present work that the co-delivery of mRNA and gardiquimod led to the effective antigen expression and DC maturation in vitro. The intravenous administration of the hybrid nanovaccine resulted in the enrichment of mRNA expression in the spleen and a strong immune response in vivo. The simultaneous delivery of the antigen and adjuvant both spatially and temporally via the core/shell nanoparticle carrier is found to be beneficial for tumor growth inhibition.
Persistent Identifierhttp://hdl.handle.net/10722/289319
ISSN
2019 Impact Factor: 6.895
2015 SCImago Journal Rankings: 2.969

 

DC FieldValueLanguage
dc.contributor.authorYang, J-
dc.contributor.authorARYA, S-
dc.contributor.authorLung, P-
dc.contributor.authorLIN, Q-
dc.contributor.authorHuang, J-
dc.contributor.authorLi, Q-
dc.date.accessioned2020-10-22T08:10:58Z-
dc.date.available2020-10-22T08:10:58Z-
dc.date.issued2019-
dc.identifier.citationNanoscale, 2019, v. 11 n. 45, p. 21782-21789-
dc.identifier.issn2040-3364-
dc.identifier.urihttp://hdl.handle.net/10722/289319-
dc.description.abstractFor efficient cancer vaccines, the antitumor function largely relies on cytotoxic T cells, whose activation can be effectively induced via antigen-encoding mRNA, making mRNA-based cancer vaccines an attractive approach for personalized cancer therapy. While the liposome-based delivery system enables the systemic delivery and transfection of mRNA, incorporating an adjuvant that is non-lipid like remains challenging, although the co-delivery of mRNA (antigen) and effective adjuvant is key to the activation of the cytotoxic T cells. This is because the presence of an adjuvant is important for dendritic cell maturation—another necessity for cytotoxic T cell activation. In the present work, we designed a poly (lactic-co-glycolic acid) (PLGA)-core/lipid-shell hybrid nanoparticle carrier for the co-delivery of mRNA and gardiquimod (adjuvant that cannot be incorporated into the lipid shell). We demonstrated in the present work that the co-delivery of mRNA and gardiquimod led to the effective antigen expression and DC maturation in vitro. The intravenous administration of the hybrid nanovaccine resulted in the enrichment of mRNA expression in the spleen and a strong immune response in vivo. The simultaneous delivery of the antigen and adjuvant both spatially and temporally via the core/shell nanoparticle carrier is found to be beneficial for tumor growth inhibition.-
dc.languageeng-
dc.publisherRSC Publications. The Journal's web site is located at http://pubs.rsc.org/en/journals/journalissues/nr#!recentarticles&all-
dc.relation.ispartofNanoscale-
dc.subjectAntigen expression-
dc.subjectCore/shell nanoparticles-
dc.subjectDelivery systems-
dc.subjectHybrid nanoparticle-
dc.subjectIntravenous administration-
dc.titleHybrid nanovaccine for the co-delivery of the mRNA antigen and adjuvant-
dc.typeArticle-
dc.identifier.emailHuang, J: jdhuang@hku.hk-
dc.identifier.authorityHuang, J=rp00451-
dc.description.naturepostprint-
dc.identifier.doi10.1039/C9NR05475H-
dc.identifier.pmid31709434-
dc.identifier.scopuseid_2-s2.0-85075630311-
dc.identifier.hkuros316037-
dc.identifier.volume11-
dc.identifier.issue45-
dc.identifier.spage21782-
dc.identifier.epage21789-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats